| 1 |
Keystone E, Heijde Dv, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-3329.
DOI
|
| 2 |
Kumar N, Naz S, Quinn M, Ryan J, Kumke T, Sheeran T. Treatment of rheumatoid arthritis with certolizumab pegol: results from PROACTIVE, a non-interventional study in the UK and Ireland. Adv Ther 2018;35:1426-1437.
DOI
|
| 3 |
Weinblatt ME, Fleischmann R, van Vollenhoven RF, et al. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Res Ther 2015;17:325.
DOI
|
| 4 |
Ebina K, Hashimoto M, Yamamoto W, et al. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis: the ANSWER cohort study. PLoS One 2018;13:e0194130.
DOI
|
| 5 |
Bluett J, Barton A. Precision medicine in rheumatoid arthritis. Rheum Dis Clin North Am 2017;43:377-387.
DOI
|
| 6 |
Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-977.
DOI
|
| 7 |
Kaushik VV, Moots RJ. CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin Biol Ther 2005;5:601-606.
DOI
|
| 8 |
Ruiz Garcia V, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Bernal JA. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2017;9:CD007649.
|
| 9 |
Kang YM, Park YE, Park W, et al. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis. Korean J Intern Med 2018;33:1224-1233.
DOI
|
webmaster
